Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Sponsor: Ascletis Pharma (China) Co., Limited
Summary
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.
Official title: A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3003
Start Date
2026-08
Completion Date
2028-07
Last Updated
2026-08-03
Healthy Volunteers
No
Interventions
ASC30 tablets A1
ASC30 tablets A1 administered orally once daily.
Placebo
Matching placebo tablets administered orally once daily.